-transparent.png){kind=logo}
A new synthetic anthraquinone, dihydroxyanthraquinone (DHAQ), was tested as a single agent and in combination with whole-body x-irradiation in mice bearing L1210 leukemia in the ascites form. DHAQ alone had significant antitumor activity as evidenced by prolonged mean survival times; radiation was ineffective. The combination of the two modalities produced a therapeutic benefits greater than that produced by either agent alone: mean survival times were increased and a number of cures (animals alive at 30 days) produced. These results suggest the potential of using DHAQ and radiation in a combined modality therapeutic approach.
Related Publications
B F Kimler, and
M P Hacker
August 1982,
Cancer treatment reports,
B F Kimler, and
M P Hacker
March 1978,
Journal of the National Cancer Institute,
B F Kimler, and
M P Hacker
July 1983,
Cancer research,
B F Kimler, and
M P Hacker
January 1978,
Biokhimiia (Moscow, Russia),
B F Kimler, and
M P Hacker
January 1980,
Neoplasma,
B F Kimler, and
M P Hacker
October 2007,
The Journal of veterinary medical science,
B F Kimler, and
M P Hacker
October 2010,
Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials,
B F Kimler, and
M P Hacker
January 1994,
Archivum immunologiae et therapiae experimentalis,
B F Kimler, and
M P Hacker
January 1980,
Cancer research,
B F Kimler, and
M P Hacker
December 1976,
Experientia,
